Nova Eye Medical Announces Q1 Results and FY26 Guidance
Nova Eye Medical Limited (ASX:EYE), a medical technology company, announced its Q1 results and provided guidance for FY26.
The company, which focuses on designing and manufacturing ophthalmic treatment technologies, held an investor webinar to discuss the details.
Key Highlights
- Sales revenue for the quarter reached US$4.854 million, a 20% increase compared to the prior corresponding period (PCP).
- Nova Eye Medical’s leading product is iTrack Advance, a minimally invasive glaucoma surgical device with approvals in major global markets.
No additional quotes available in the text.
Author's summary: Nova Eye Medical announces Q1 results.